Humana Inc. stock rises 5.83% to $243.12, outperforming competitors

4 articles · Updated · MarketWatch · Apr 29

Humana shares gained for a fourth consecutive day, closing 22.90% below their 52-week high of $315.35.
The stock's trading volume surged to 4.0 million, well above its 50-day average of 1.7 million shares.
Despite a generally weak market session, Humana outperformed rivals like UnitedHealth and Elevance Health, while Chubb Ltd. declined.

Humana's stock surged despite a lowered profit forecast. Is this rally built to last?

Why does one valuation model suggest Humana's stock is worth double Wall Street's target?

Can Humana's partnership with Mark Cuban's company truly disrupt high prescription drug prices?

As GLP-1 drug costs drive premium hikes, what is Humana's plan to control these expenses?

With Humana prioritizing margins over membership, will seniors face higher costs or fewer benefits?

How will proposed new prior authorization rules impact Humana's profitability and operations?